Ian Fearon is an independent consultant with expertise in regulatory and scientific aspects of nicotine and tobacco products. His consulting work encompasses clinical and behavioural studies of tobacco and nicotine products for regulatory submissions in the US and Europe, and he has a wealth of experience of both consumer goods and medicinal licensing submissions.  His 15 years working in the Tobacco Harm Reduction arena has included roles as Senior Director of Clinical and Regulatory Affairs EMEA with JUUL Labs, Director of Tobacco Research with Celerion, and Principal Scientist and Head of Clinical Research at British American Tobacco. 

Scott J. Leischow, Ph.D. joined the Mayo Clinic in 2012, where he leads the Research on Health Equity and Community Health (REACH) Program at Mayo Clinic Arizona, and co-leads Cancer Prevention and Control within the Mayo Clinic Cancer Center. He was formerly University of Arizona and also served as Senior Advisor for Tobacco Policy in the US Department of Health and Human Services and Chief of the Tobacco Control Research Branch at the National Cancer Institute of NIH. Dr. Leischow completed his doctorate in Health Education from the University of Maryland, and a postdoctoral fellowship in Behavioral Pharmacology from Johns Hopkins University. Dr. Leischow has received several awards, including the NIH Director’s Award. Most of Dr. Leischow’s research and publications focus on pharmacologic and behavioral treatments for tobacco dependence, along with systems and network approaches to public health. Dr. Leischow is past President of the Society for Research on Nicotine and Tobacco (SRNT).